NCT03161132 - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

February 7, 2020

Study Completion Date

December 31, 2022

Conditions

Advanced Ovarian Cancer

Interventions

DRUG

Olaparib

Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.

DRUG

Pegylated Liposomal Doxorubicin

PLD 40mg/m2 every 28 days intravenous

Trial Locations (8)

28034

Hospital Universitario Ramón y Cajal, Madrid

46009

Hospital Universitario y Politécnico La Fe, Valencia

Unknown

Corporación Sanitaria Parc Taulí, Sabadell

Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria

Hospital Son Llatzer, Palma de Mallorca

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Virgen del Rocío, Seville

Hospital Clínico Universitario de Valencia, Valencia